$ACOR News
Last published 2y ago
- 2y agoACORACORQAcorda Therapeutics Announces Delisting from NasdaqBusiness WireAcorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules
- 2y agoACORAcorda Therapeutics Announces Nasdaq Delisting NotificationBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the
- 2y agoACORAcorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase AgreementBusiness WireAcorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders Patient Access to INBRIJA®
- 2y agoACORAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company
- 2y agoACORAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To
- 2y agoACORAcorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced it will regain global commercialization rights to FAMPYRA® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement
- 2y agoACORAcorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoACORAcorda Therapeutics Reports Third Quarter 2023 Financial ResultsBusiness WireINBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA
- 3y agoACORAcorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its third quarter 2023 update and financial results on Monday, November 13 at 4:30 p.m. ET. To participate in the
- 3y agoACORAcorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®Business WireUp to five approvals expected in 2024 Additional filings expected in Chile in late 2023 and in Mexico and Brazil in 2024 Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced the submission of new regulatory
- 3y agoACORAcorda Therapeutics Reports Second Quarter 2023 Financial ResultsBusiness WireINBRIJA® (levodopa inhalation powder) Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million New INBRIJA prescription request forms increased 42% in 1H 2023
- 3y agoACORAcorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters™"Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign. The campaign, "For the Fighters," is based on direct feedback from
- 3y agoACORAcorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m. ET. To participate in the Webcast,
- 3y agoACORTom Burns Elected to the Acorda Therapeutics Board of DirectorsBusiness WireJeff Randall Rotates off the Board Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Tom Burns, Chief Financial Officer at XOMA Corporation, has been elected to its Board of Directors by the stockholders at
- 3y agoACORAcorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price RequirementBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price
- 3y agoACORAcorda Therapeutics Announces Completion of 1-for-20 Reverse Stock SplitBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split
- 3y agoACORAcorda Therapeutics to Conduct 1-for-20 Reverse Stock SplitBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split will become
- 3y agoACORTOLLAcorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&ABusiness WireJune 7, 2023 at 1pm ET, 10am PT Participants Invited to Submit Questions to the CEO Acorda Therapeutics, Inc. (NASDAQ:ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Wednesday, June 7 at
- 3y agoACORAcorda Therapeutics Reports First Quarter 2023 Financial ResultsBusiness WireINBRIJA® (levodopa inhalation powder) Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q1
- 3y agoACORAcorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in CashBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will make a cash interest payment of approximately $6.2 million due on June 1, 2023 under its Convertible Senior Secured Notes Indenture. Under the terms
- 3y agoACORIMRNLLYSILO+1Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027PR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 9, 2023 /PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which
- 3y agoACORAcorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in ChinaBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in China. INBRIJA is indicated
- 3y agoACORAcorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its first quarter 2023 update and financial results on Thursday, May 11 at 4:30 p.m. ET. To participate in the Webcast,
- 3y agoACORAcorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual MeetingBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will present data on INBRIJA (levodopa inhalation powder) and OFF Periods at the American Academy of Neurology (AAN) Annual Meeting, taking place in Boston
- 3y agoACORAcorda Launches INBRIJA® TV Commercial for Parkinson's Awareness MonthBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has launched an INBRIJA® (levodopa inhalation powder) television commercial for Parkinson's Awareness Month. The commercial will air on
- 3y agoACORTOLLAcorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&ABusiness WireApril 4, 2023 at 1pm ET, 10am PT Participants Invited to Submit Questions to the CEO Acorda Therapeutics, Inc. (NASDAQ:ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Tuesday, April 4 at
- 3y agoACORAcorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsBusiness WireINBRIJA® (levodopa inhalation powder) 2022 U.S. net revenue of $28.0MM and ex-U.S. net revenue of $2.9MM; Q4 2022 U.S. net revenue of $9.0MM AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2022 net
- 3y agoACORESTEVE Launches INBRIJA® in SpainBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU for the intermittent
- 3y agoACORAcorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2022 update and financial results on Thursday, March 9 at 8:30 a.m. ET. To participate in
- 3y agoACORAcorda Therapeutics to Present at Sequire Biotechnology ConferenceBusiness WirePresentation on Thursday, February 2, 2023 at 3:00 p.m. ET Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, will make a virtual presentation at the
- 3y agoACORAcorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®Business WireSignificant reduction in minimum purchase requirements 2026 manufacturing capacity expansion expected to result in further reductions in cost of goods Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that on
- 3y agoACORAcorda Therapeutics Announces Revised Long-Term Financial GuidanceBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for
- 3y agoACORAcorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a HearingBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company's common stock not having regained compliance
- 3y agoACORAcorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in CashBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture. Acorda may elect
- 4y agoACORAcorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of StockholdersBusiness WireAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company's stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders.
- 4y agoACORAcorda Therapeutics Announces Adjournment of Special Meeting of StockholdersBusiness WireScheduled to Reconvene November 11, 2022 at 9:00 a.m. Eastern Time at the Company's Headquarters to Vote on Proposal Two
- 4y agoACORALKSAcorda Therapeutics Reports Third Quarter 2022 Financial ResultsBusiness WireINBRIJA® (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 AMPYRA® (dalfampridine) Q3 2022 net revenue of $21.1 million; 5% increase over Q3 2021 $16.5M award
- 4y agoACORAcorda Therapeutics Provides Long-Term Business Plan and Financial GuidanceBusiness WireCEO video / Q&A with shareholders on October 28, 2022 to review business plan and ballot items for special meeting of stockholders Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a detailed, long-term
- 4y agoACORAcorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m. ET. To participate in the Webcast,
- 4y agoACORTOLLAcorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.Business WireOctober 28, 2022 at 1pm ET, 10am PT Shareholders are invited to submit questions to the CEO Acorda Therapeutics, Inc. (NASDAQ:ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October
- 4y agoACORISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock SplitBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that the three leading, independent proxy advisory firms - Institutional Shareholder Services (ISS), Glass Lewis and Co, LLC, and Egan-Jones & Co - all
- 4y agoACORAcorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured DebtBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will not use its common stock to make the approximately $6.2 million interest payment due on December 1, 2022, as provided for under its Convertible Senior
- 4y agoACORALKSAcorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration CaseBusiness Wire$16.5 million to recover past royalties and interest Cessation of double-digit royalty/supply payments Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that a three-judge arbitration panel has issued a final
- 4y agoACORAcorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of StockholdersBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that the company has withdrawn Proposal One, a request to increase the number of authorized shares of Acorda stock, from the ballot for the Special Meeting of
- 4y agoACORAcorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment ConferenceBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 3 p.m. ET. The confe
- 4y agoACORAcorda Therapeutics Enters into License Agreement with Asieris PharmaceuticalsBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agre
- 4y agoACORAcorda Therapeutics Announces Resignation of Chief Operating OfficerBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology compa
- 4y agoACORAcorda Therapeutics Reports Second Quarter 2022 Financial ResultsBusiness WireINBRIJA® (levodopa inhalation powder) Q2 2022 U.S. net revenue of $7.4 million; 16% increase from Q2 2021; 100% increase over Q1 2022 Ex-U.S. INBRIJA Q2 additional revenue of $1.9 million AMPYRA® (dalfampridine) Q2 2022 net revenue of $18.2
- 4y agoACORAcorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022Business WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its second quarter 2022 update and financial results on Thursday, August 4 at 4:30 p.m. ET. To participate in the Webcast, please use the following regist
- 4y agoACOREsteve Launches INBRIJA® in GermanyBusiness WireAcorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor